FRONTAGE (01521) receives privatization proposal at approximately 59.1% premium; trading to resume on November 10.
FRONTAGE (01521) and the offeror SanRex Limited jointly announced that on November 9, 2026, the offeror and the company entered into an implementation agreement, pursuant to which the parties have agreed to use all reasonable efforts to implement a proposal to privatize the company by way of a scheme of arrangement under section 86 of the Companies Law. If the proposal is approved and implemented, the cancellation price per scheme share will be HK$2.370, representing a premium of approximately 59.1% over the closing price of HK$1.490 per share as quoted on the Stock Exchange on the last trading day.
FRONTAGE (01521) and the offeror SanRex Limited jointly announced that on November 9, 2026, the offeror and the company entered into an implementation agreement, pursuant to which the parties have agreed to use all reasonable efforts to implement the proposal to privatize the company by way of a scheme of arrangement under section 86 of the Companies Law. If the proposal is approved and implemented, the cancellation price per scheme share will be HK$2.370, representing a premium of approximately 59.1% over the closing price of HK$1.490 per share as quoted on the Stock Exchange on the last trading day.
Upon the scheme becoming effective, all scheme shares will be cancelled (and an equal number of new shares will be issued to the offeror, credited as fully paid, to maintain the company's issued share capital at the amount immediately prior to the cancellation of the scheme shares), and the share certificates for the scheme shares will thereafter cease to have effect as documents or evidence of title. Immediately following the effective date, the company will apply to withdraw the listing of the shares on the Stock Exchange pursuant to Rule 6.15 of the Listing Rules. The company has applied to the Stock Exchange for resumption of trading in the shares on the Stock Exchange with effect from 9:00 a.m. (Hong Kong time) on November 10, 2026.
As at the date of this announcement, the offeror's issued share capital is 2,038,538,910 shares with a par value of US$0.00001 each, and is owned as to 38.27%, 53.40%, 1.63%, 2.24%, 2.24% and 2.24% by CRL, Hong Kong Tigermed, Dr. Li Song (Chairman of the Board), The Linna Li GST Exempt Trust, The Wendy Li GST Exempt Trust and The Yue Monica Li GST Exempt Trust, respectively. As at the date of this announcement, the offeror is a non-wholly-owned subsidiary of Hangzhou Tigermed Consulting, and the offeror shares held by Hong Kong Tigermed, Dr. Li Song (Chairman of the Board), The Linna Li GST Exempt Trust, The Wendy Li GST Exempt Trust and The Yue Monica Li GST Exempt Trust respectively remain unpaid.
Related Articles

US Stock Market Move | Storage sector strengthens collectively; Western Digital Corporation (WDC.US) rises over 8%.

Eli Lilly (LLY.US) Weight-Loss Oral Drug Foundayo Shows Significant Efficacy in Treating Sleep Apnea; Plans to Seek FDA Approval by Year-End

A-share Evening Highlights | Iran signals willingness to negotiate! Oil prices plunge, gold rallies
US Stock Market Move | Storage sector strengthens collectively; Western Digital Corporation (WDC.US) rises over 8%.

Eli Lilly (LLY.US) Weight-Loss Oral Drug Foundayo Shows Significant Efficacy in Treating Sleep Apnea; Plans to Seek FDA Approval by Year-End

A-share Evening Highlights | Iran signals willingness to negotiate! Oil prices plunge, gold rallies






